Thu, Apr 29, 2021 11:30 AM – 12:30 PM EDT Register Real-world data is increasingly being used to develop external control arms for trial planning and regulatory submissions. Understanding the basics of what they are and how they can be used effectively are critical to success. Join Dr. Richard Gliklich, CEO of OM1, as he[…]
BOSTON, April 8, 2021 /PRNewswire/ — OM1, a real-world outcomes and technology company, today announced a strategic collaboration with the American Academy of Dermatology (AAD) connecting the Academy’s DataDerm™ clinical data registry to OM1’s real-world data and evidence platforms. The AAD estimates that 1 in 4 Americans (more than 85 million) see a physician for[…]
M.D. Alert Published: March 5, 2021 Read the Full Commentary >> (Reuters Health) – Women have better screening outcomes with digital breast tomosynthesis, but a new study suggests that Black women have less access to this imaging modality. Researchers examined data on 385,503 women screened at one of 63 U.S. breast imaging facilities between 2015[…]
Thu, Mar 18, 2021 11:30 AM – 12:30 PM EDT Register Automated data networks are transforming prospective research by adding value in ways not possible with traditional registries. This webinar challenges the status quo and explores innovative approaches to building and leveraging data networks for succeeding in the new world of real-world data and multi-stakeholder[…]
BOSTON, Feb. 18, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), health outcomes and technology company, today announced the publication of clinical trial results in JAMA Network Open demonstrating its tool, OM1™ Joint Insights, positively impacts decision quality, shared decision making, patient experience, and functional outcomes in adults with knee osteoarthritis (OA). In the U.S., more than 30 million adults[…]
